(Reuters) - Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant ...
Vipin Garg, Altimmune CEO, joins 'Fast Money' to discuss Altimmune announcing topline results from its obesity drug trial, ...
Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made ...
Viking Therapeutics shows strong data with VK2735, a potential competitor to major drugs. Discover why VKTX stock is a ...
That criteria makes 3.4 million patients in England eligible for the treatment, but over the next three years, access will be restricted to about 220,000 people with the “highest clinical need” – or 6 ...
The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible ...
U.S. Food and Drug Administration Commissioner Robert Califf defended the agency's role in addressing the country's obesity ...
The U.K. will start offering Eli Lilly’s weight loss drug next year, but will restrict the medicine to people with the ...
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...
Following its endorsement of Eli Lilly’s obesity medicine tirzepatide, England’s National Institute for Health and Care ...
Wall Street is chewing over data on Amgen’s weight loss injection, MariTde. Meanwhile, GE HealthCare will acquire a Japanese ...
Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with ...